Moolec Science (MLEC) Non-Current Deferred Tax Liability (2023 - 2026)
Moolec Science (MLEC) reported Non-Current Deferred Tax Liability of $14.3 million for Q1 2026, little changed sequentially from $14.3 million in Q4 2025.
Moolec Science (MLEC) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Moolec Science (MLEC) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $14.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $14.3 million; the trailing twelve-month figure through Mar 2026 stood at $14.3 million (changed N/A YoY), and the FY2025 full-year result was $14.4 million, down 58.18% from the prior year.
- Non-Current Deferred Tax Liability was little changed at $14.3 million in Q1 2026, from $14.3 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $34.5 million in Q2 2024 to a low of $40491.0 in Q3 2024.
- A 4-year average of $7.5 million and a median of $1.1 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- Across the five-year window, Non-Current Deferred Tax Liability plunged 95.2% in 2024 and soared 4424.96% in 2025, its largest moves.
- Tracing MLEC's Non-Current Deferred Tax Liability over 4 years: stood at $323391.0 in 2023, then dropped by 2.27% to $316039.0 in 2024, then soared by 4424.96% to $14.3 million in 2025, then decreased by 0.0% to $14.3 million in 2026.
- Business Quant data shows MLEC's Non-Current Deferred Tax Liability at $14.3 million in Q1 2026, $14.3 million in Q4 2025, and $14.4 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.30 Mn |
| Mar 31, 2026 | 14.30 Mn |
| Dec 31, 2025 | 14.30 Mn |
| Dec 31, 2025 | 14.30 Mn |
| Jun 30, 2025 | 14.43 Mn |
| Jun 30, 2025 | 14.43 Mn |
| Dec 31, 2024 | 316,039.00 |
| Dec 31, 2024 | 316,039.00 |
| Sep 30, 2024 | 40,491.00 |
| Sep 30, 2024 | 40,491.00 |
| Jun 30, 2024 | 34.50 Mn |
| Jun 30, 2024 | 34.50 Mn |
| Mar 31, 2024 | 588,965.00 |
| Mar 31, 2024 | 588,965.00 |
| Dec 31, 2023 | 323,391.00 |
| Dec 31, 2023 | 323,391.00 |
| Sep 30, 2023 | 843,032.00 |
| Sep 30, 2023 | 843,032.00 |
| Jun 30, 2023 | 1.07 Mn |
| Jun 30, 2023 | 1.07 Mn |